Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission.

MLA

Ooms, Maarten, et al. “Striatal Phosphodiesterase 10A Availability Is Altered Secondary to Chronic Changes in Dopamine Neurotransmission.” EJNMMI Radiopharmacy & Chemistry, vol. 1, no. 1, Mar. 2016, pp. 1–17. EBSCOhost, https://doi.org/10.1186/s41181-016-0005-5.

APA

Ooms, M., Celen, S., De Hoogt, R., Lenaerts, I., Liebregts, J., Vanhoof, G., Langlois, X., Postnov, A., Koole, M., Verbruggen, A., Van Laere, K., & Bormans, G. (2016). Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission. EJNMMI Radiopharmacy & Chemistry, 1(1), 1–17. https://doi.org/10.1186/s41181-016-0005-5

Chicago

Ooms, Maarten, Sofie Celen, Ronald De Hoogt, Ilse Lenaerts, Johnny Liebregts, Greet Vanhoof, Xavier Langlois, et al. 2016. “Striatal Phosphodiesterase 10A Availability Is Altered Secondary to Chronic Changes in Dopamine Neurotransmission.” EJNMMI Radiopharmacy & Chemistry 1 (1): 1–17. doi:10.1186/s41181-016-0005-5.